BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ramadass M, Ghebrehiwet B, Smith RJ, Kew RR. Generation of multiple fluid-phase C3b:plasma protein complexes during complement activation: possible implications in C3 glomerulopathies. J Immunol 2014;192:1220-30. [PMID: 24367026 DOI: 10.4049/jimmunol.1302288] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Vu VP, Gifford GB, Chen F, Benasutti H, Wang G, Groman EV, Scheinman R, Saba L, Moghimi SM, Simberg D. Immunoglobulin deposition on biomolecule corona determines complement opsonization efficiency of preclinical and clinical nanoparticles. Nat Nanotechnol 2019;14:260-8. [PMID: 30643271 DOI: 10.1038/s41565-018-0344-3] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 31.7] [Reference Citation Analysis]
2 Gaikwad H, Li Y, Wang G, Li R, Dai S, Rester C, Kedl R, Saba L, Banda NK, Scheinman RI, Patrick C, Mallela KMG, Moghimi SM, Simberg D. Antibody-Dependent Complement Responses toward SARS-CoV-2 Receptor-Binding Domain Immobilized on "Pseudovirus-like" Nanoparticles. ACS Nano 2022. [PMID: 35507641 DOI: 10.1021/acsnano.2c02794] [Reference Citation Analysis]
3 Welte T, Arnold F, Kappes J, Seidl M, Häffner K, Bergmann C, Walz G, Neumann-Haefelin E. Treating C3 glomerulopathy with eculizumab. BMC Nephrol 2018;19:7. [PMID: 29329521 DOI: 10.1186/s12882-017-0802-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
4 Kamel MH, Jaberi A, Gordon CE, Beck LH, Francis J. The Complement System in the Modern Era of Kidney Transplantation: Mechanisms of Injury and Targeted Therapies. Seminars in Nephrology 2022;42:14-28. [DOI: 10.1016/j.semnephrol.2022.01.006] [Reference Citation Analysis]
5 De Vriese AS, Sethi S, Van Praet J, Nath KA, Fervenza FC. Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach. J Am Soc Nephrol. 2015;26:2917-2929. [PMID: 26185203 DOI: 10.1681/asn.2015020184] [Cited by in Crossref: 53] [Cited by in F6Publishing: 27] [Article Influence: 7.6] [Reference Citation Analysis]
6 Van de Walle I, Silence K, Budding K, Van de Ven L, Dijkxhoorn K, de Zeeuw E, Yildiz C, Gabriels S, Percier JM, Wildemann J, Meeldijk J, Simons PJ, Boon L, Cox L, Holgate R, Urbanus R, Otten HG, Leusen JHW, Blanchetot C, de Haard H, Hack CE, Boross P. ARGX-117, a therapeutic complement inhibiting antibody targeting C2. J Allergy Clin Immunol 2021;147:1420-1429.e7. [PMID: 32926878 DOI: 10.1016/j.jaci.2020.08.028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
7 Nissilä E, Hakala P, Leskinen K, Roig A, Syed S, Van Kessel KPM, Metso J, De Haas CJC, Saavalainen P, Meri S, Chroni A, Van Strijp JAG, Öörni K, Jauhiainen M, Jokiranta TS, Haapasalo K. Complement Factor H and Apolipoprotein E Participate in Regulation of Inflammation in THP-1 Macrophages. Front Immunol 2018;9:2701. [PMID: 30519244 DOI: 10.3389/fimmu.2018.02701] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
8 Ghosh S, Das S, Mukherjee J, Abdullah S, Mondal R, Sultana S, Sehgal A, Behl T. Enumerating the role of properdin in the pathogenesis of IgA nephropathy and its possible therapies. Int Immunopharmacol 2021;93:107429. [PMID: 33571820 DOI: 10.1016/j.intimp.2021.107429] [Reference Citation Analysis]
9 Haapasalo K, van Kessel K, Nissilä E, Metso J, Johansson T, Miettinen S, Varjosalo M, Kirveskari J, Kuusela P, Chroni A, Jauhiainen M, van Strijp J, Jokiranta TS. Complement Factor H Binds to Human Serum Apolipoprotein E and Mediates Complement Regulation on High Density Lipoprotein Particles. J Biol Chem 2015;290:28977-87. [PMID: 26468283 DOI: 10.1074/jbc.M115.669226] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
10 O'Brien ME, Murray G, Gogoi D, Yusuf A, McCarthy C, Wormald MR, Casey M, Gabillard-Lefort C, McElvaney NG, Reeves EP. A Review of Alpha-1 Antitrypsin Binding Partners for Immune Regulation and Potential Therapeutic Application. Int J Mol Sci 2022;23:2441. [PMID: 35269582 DOI: 10.3390/ijms23052441] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 O'Brien ME, Fee L, Browne N, Carroll TP, Meleady P, Henry M, McQuillan K, Murphy MP, Logan M, McCarthy C, McElvaney OJ, Reeves EP, McElvaney NG. Activation of complement component 3 is associated with airways disease and pulmonary emphysema in alpha-1 antitrypsin deficiency. Thorax 2020;75:321-30. [PMID: 31959730 DOI: 10.1136/thoraxjnl-2019-214076] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
12 Ramadass M, Ghebrehiwet B, Kew RR. Enhanced recognition of plasma proteins in a non-native state by complement C3b. A possible clearance mechanism for damaged proteins in blood. Mol Immunol 2015;64:55-62. [PMID: 25466612 DOI: 10.1016/j.molimm.2014.10.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
13 Filippone EJ, Newman ED, Li L, Gulati R, Farber JL. Thrombotic Microangiopathy, an Unusual Form of Monoclonal Gammopathy of Renal Significance: Report of 3 Cases and Literature Review. Front Immunol 2021;12:780107. [PMID: 34858436 DOI: 10.3389/fimmu.2021.780107] [Reference Citation Analysis]